HLA Binding Affinity-based Screening of Neoantigens

The ultimate goal of various immunotherapeutic strategies against tumor neoantigens is to elicit and/or expand tumor-specific T cell responses. Due to the limitations of the vaccine manufacturing cycle and the development of the patient's condition, it is difficult for many clinical studies on tumor neoantigens to have sufficient time to verify the immunological properties of the predicted candidate tumor neoantigens. The identification of neoantigens mainly uses genomic technologies such as next-generation sequencing and high-throughput single-cell sequencing; proteomic technologies such as mass spectrometry; bioinformatics tools based on high-throughput sequencing data, mass spectrometry data, and biological databases.

Category: General